| Population 2017 |
26 million |
| |
| | | | | |
| Estimates of TB burden*, 2017 |
Number (thousands) |
Rate
(per 100 000 population) |
| Mortality (excludes HIV+TB) |
13 |
(7.8–20) |
52 |
(31–79) |
| Mortality (HIV+TB only) |
0.65 |
(0.29–1.2) |
2.6 |
(1.1–4.5) |
| Incidence (includes HIV+TB) |
61 |
(39–87) |
238 |
(154–340) |
| Incidence (HIV+TB only) |
1.5 |
(0.69–2.7) |
6 |
(2.7–11) |
| Incidence (MDR/RR-TB)** |
0.44 |
(0.087–1.1) |
1.7 |
(0.34–4.2) |
| |
| | | | | |
| Estimated TB incidence by age and sex (thousands)*, 2017 |
| |
0-14 years |
> 14 years |
Total |
| Females |
3.7 |
(3.4–4.1) |
19 |
(15–24) |
23 |
(18–29) |
| Males |
4.1 |
(3.7–4.6) |
33 |
(24–43) |
38 |
(26–49) |
| Total |
7.9 |
(6.8–9) |
53 |
(34–72) |
61 |
(39–87) |
| |
| | | | | |
| TB case notifications, 2017 |
|
| Total cases notified |
31 783 |
| Total new and relapse |
31 370 |
| - % tested with rapid diagnostics at time of diagnosis |
|
| - % with known HIV status |
50% |
| - % pulmonary |
80% |
| - % bacteriologically confirmed among pulmonary |
87% |
| |
| | | | | |
| Universal health coverage and social protection |
|
| TB treatment coverage (notified/estimated incidence), 2017 |
52% (36–80) |
| TB patients facing catastrophic total costs |
|
| TB case fatality ratio (estimated mortality/estimated incidence), 2017 |
0.24 (0.12–0.39) |
| |
| | | | | |
| TB/HIV care in new and relapse TB patients, 2017 |
Number |
(%) |
| Patients with known HIV-status who are HIV-positive |
156 |
<1% |
| - on antiretroviral therapy |
70 |
45% |
| |
| | | | | |
| Drug-resistant TB care, 2017 |
New cases |
Previously treated
cases |
Total
number*** |
Estimated MDR/RR-TB cases among notified
pulmonary TB cases |
|
250
(13–490) |
| Estimated % of TB cases with MDR/RR-TB |
0.49% (0.09–1.2) |
5.9% (0.59–17) |
|
| % notified tested for rifampicin resistance |
0% |
26% |
612 |
| MDR/RR-TB cases tested for resistance to second-line drugs |
|
17 |
| Laboratory-confirmed cases |
MDR/RR-TB: 30, XDR-TB: 0 |
| Patients started on treatment **** |
MDR/RR-TB: 18, XDR-TB: 0 |
| |
| | | | | |
| Treatment success rate and cohort size |
Success |
Cohort |
| New cases registered in 2016 |
84% |
27 818 |
| Previously treated cases registered in 2016 |
79% |
2 120 |
| HIV-positive TB cases registered in 2016 |
|
0 |
| MDR/RR-TB cases started on second-line treatment in 2015 |
57% |
7 |
| XDR-TB cases started on second-line treatment in 2015 |
|
0 |
| |
| | | | | |
| TB preventive treatment, 2017 |
|
| % of HIV-positive people (newly enrolled in care) on preventive treatment |
9% |
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment |
23% (21–25) |
| |
| | | | | |
| TB financing, 2018 |
|
| National TB budget (US$ millions) |
2.7 |
| Funding source: domestic, 122% international, <1% unfunded |
| |
| | | | | |
| * Ranges represent uncertainty intervals | | | | | |
| ** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin | | | |
| *** Includes cases with unknown previous TB treatment history | | | | |
| **** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed | | |
| | | | | |